Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Medifast ( (MED) ).
On December 30, 2025, Medifast, Inc. agreed that Chief Business Operations Officer and named executive officer Anthony Tyree would leave the company effective December 31, 2025, in a departure stated as unrelated to any disagreements over operations or policies. Under a separation agreement with subsidiary Jason Pharmaceuticals, Tyree is to receive a lump-sum payment equal to one year of salary and target bonus, eligibility for a 2025 bonus based on actual performance, prorated vesting of restricted and performance share units through year-end 2025, extended health coverage at active-employee rates through December 31, 2026 if COBRA is elected, and up to six months of outplacement assistance, in exchange for standard noncompetition, confidentiality and non-disparagement covenants. Effective January 5, 2026, the company promoted Nicholas Johnson from Chief Field Operations Officer to President of Medifast, broadening his remit to include enterprise marketing, scientific and clinical affairs, product development, and consumable product and plan management, while CFO James Maloney assumes oversight of the supply chain function—moves that underscore Johnson’s role in CEO succession planning and signal a tightening of operational control. Also on January 5, 2026, Chairman and CEO Daniel Chard announced he will transition to non-executive Chairman of the Board effective June 1, 2026, under a letter agreement that reduces his salary, target bonus and long-term incentive opportunity during the remaining period of his executive tenure, then shifts him to a board retainer structure while allowing continued vesting of existing equity awards so long as he remains non-executive chairman, a package that formalizes leadership succession while maintaining continuity for shareholders and the board.
The most recent analyst rating on (MED) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Medifast stock, see the MED Stock Forecast page.
Spark’s Take on MED Stock
According to Spark, TipRanks’ AI Analyst, MED is a Neutral.
Medifast’s overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, including declining revenue and profitability, as well as cash flow issues. Technical indicators suggest bearish momentum, with the stock trading below key moving averages and showing oversold conditions. The high P/E ratio indicates potential overvaluation. While the earnings call highlighted some positive strategic initiatives, the substantial revenue decline and decrease in active coaches remain concerns.
To see Spark’s full report on MED stock, click here.
More about Medifast
Medifast, Inc. operates in the health and wellness industry through meal-replacement and weight-management programs, primarily marketed under its OPTAVIA brand. The company focuses on structured nutrition plans and coaching-based offerings aimed at consumers seeking weight loss and healthy-living solutions, supported by a direct selling model and related field and technology operations.
Average Trading Volume: 216,584
Technical Sentiment Signal: Sell
Current Market Cap: $114.3M
For detailed information about MED stock, go to TipRanks’ Stock Analysis page.